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A B S T R A C T
Background
Adults with severe mental illness (i.e. schizophrenia or other related psychotic disorders and bipolar disorder) can be at greater risk of
cancer than those without severe mental illness (SMI). Early detection of cancer through screening is effective in improving patient
outcomes including death. However, people with SMI are less likely than others to take up available cancer screening.
Objectives
To determine the effectiveness of interventions targeted at adults with SMI, or their carers or health professionals, and aimed at
increasing the uptake of cancer screening tests for which the adults with SMI are eligible.
Search methods
We searched the Cochrane Schizophrenia Group’s Trials Register (October 25, 2012; December 19, 2014; April 07, 2015; July 04,
2016).
Selection criteria
All randomised controlled trials (RCTs) of interventions, targeted towards adults with SMI or their carers or health professionals, to
encourage uptake of cancer screening tests for which the adults with SMI were eligible.
Data collection and analysis
Two review authors independently screened titles and abstracts and assessed these against the inclusion criteria.
Main results
We did not find any trials that met the inclusion criteria.
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Authors’ conclusions
A comprehensive search showed that currently there is no RCT evidence for any method of encouraging cancer screening uptake in
people with SMI. No specific approach can therefore be recommended. High-quality, large-scale RCTs are needed urgently to help
address the disparity between people with SMI and others in cancer screening uptake.
P L A I N L A N G U A G E S U M M A R Y
Interventions to encourage cancer screening uptake in severe mental illness
Cancer is a leading cause of death worldwide, accounting for approximately 13% of all deaths in 2007. Some studies have reported
an increased incidence of cancer in people with mental health problems. The Schizophrenia Commission reports that people with
schizophrenia who develop cancer are three times more likely to die than those in the general population with cancer.
Mental illness is associated with certain health problems, including: obesity; smoking; drinking alcohol; and poor diet, all of which
increase risk of cancer. It has been estimated that approximately one-third of cancer deaths could be prevented with early detection, of
which cancer screening is the most effective method. However, people with mental illness are less likely than others to take up available
cancer screening. Reasons for non-uptake include: low income; increasing age; lack of transport; embarrassment; lack of reminders;
and lack of familiar care providers.
In the general population, telephone invitations, telephone counselling, prompts following the initial invitation and opportunistic
screening are good at increasing uptake of cancer screening. Reducing financial barriers (i.e. providing free screening tests, bus passes or
postage) may also help. GPs have also been offered incentives under the Quality and Outcomes Framework to provide regular physical
health checks to people with mental illness. People with mental illness may require more individualised care, such as more intense
counselling, to encourage screening.
A comprehensive search showed that currently there is no trial evidence for any method of encouraging uptake of cancer screening for
people with mental illness. No specific approach can therefore be recommended. Early detection of cancer through screening is effective
in improving patient outcomes, including death. Given that people with mental illness are at greater risk of cancer but less likely than
others to take up available screening, better approaches that encourage uptake of cancer screening are needed urgently. Further research
is required to ensure that people with mental illness do not miss out on cancer screening.
This plain language summary has been written by a consumer: Benjamin Gray, Service User and Service User Expert, Rethink Mental
Illness. Email: ben.gray@rethink.org
B A C K G R O U N D
Description of the condition
People with schizophrenia (and related non-organic psychotic dis-
orders) and bipolar disorder involving prolonged treatment and
disability or dysfunction are considered to have severe mental ill-
ness (SMI) (Howard 2010; Ruggeri 2000). Schizophrenia is char-
acterised by distortions of thinking and perception, often accom-
panied by delusions, hallucinations and blunting or incongruity
of emotional responses. Apathy and paucity of speech may also
develop, which can result in reduced social performance. Bipolar
disorder is characterised by repeated episodes during which the
individual’s mood and activity are substantially disturbed, alter-
nating between elevated mood and activity and decreased energy
and activity. Prevalence rates of SMI vary according to how its def-
inition is operationalised (Ruggeri 2000), but, using a conserva-
tive definition (NIMH 1987), the total population-based annual
prevalence in Europe has been found to be approximately two per
thousand (Ruggeri 2000).
Cancer is a leading cause of death worldwide, accounting for ap-
proximately 13% of all deaths in 2007 (WHO 2009). Some stud-
ies have reported an increased incidence of cancer in people with
SMI, although data are conflicting (Howard 2010; Leucht 2007).
This may be due to lack of consideration by researchers of the
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influence of missing cancer diagnoses, shortened life expectancy,
historical and health service contexts, behavioural risk factors and
genetic or drug effects (Howard 2010). However, SMI is associ-
ated with certain adverse health behaviours and health problems
(Brown 1999), including obesity (Allison 1999), smoking (Dalack
1998; McReadie 2002), drinking (McReadie 2002) and poor diet
(Osborn 2007) which predispose individuals to cancer, especially
lung and breast cancer (Howard 2010). Cancer screening (the sys-
tematic application of a test in an asymptomatic population in or-
der to identify individuals with an abnormality suggestive of a spe-
cific cancer) (WHO2007), is associatedwith reduced rates ofmor-
bidity and mortality (Anttila 2004; Botha 2003; Draisma 2003;
Rhodes 2000). It has been estimated that approximately one-third
of cancer deaths could be prevented with early detection, of which
screening is themost effectivemethod (WHO2007).Many coun-
tries offer screening routinely for a wide range of cancers including
cervical (Anttila 2004), prostate (Draisma 2003), breast (Botha
2003) and colorectal (Rhodes 2000). However, a recent review
(Howard 2010), which identified 12 studies (conducted in Ice-
land, USA, Canada, Australia, and the UK) of cancer screening
uptake in people with mental illness, concluded that adults with
SMI were less likely than other groups to receive screening for a
range of cancers (i.e. cervical, breast, colorectal, and prostate can-
cer) .
Description of the intervention
In the general population, telephone invitations, telephone coun-
selling prompts following the initial invitation and opportunis-
tic screening are effective in increasing screening uptake across a
range of screening programmes (Jepson 2000). Reducing financial
barriers (i.e. providing free screening tests, bus passes or postage)
may also be effective (Jepson 2000). Health service level inter-
ventions may also be important. A recent study (Abrams 2012),
conducted in Maryland, USA, found, in contrast to other studies
using similar methods, that cervical cancer screening was increased
in women with SMI compared with controls without SMI; study
participants were all enrolled in Maryland’s Medicaid programme
and the authors conclude that their novel findingmay be explained
by participation in this programme, which is situated in a wealthy
state that has achieved relatively high grades for its public men-
tal health system. In the UK, since 2003, GPs have been offered
incentives under the Quality and Outcomes Framework (BMA
2003) to offer regular physical health reviews to people with SMI.
Since 2006 (BMA 2006), a specific recommendation was made to
offer preventative screening appropriate to age and gender, includ-
ing mammography and cervical screening. It is not known what
effect this has had on screening uptake in people with SMI in the
UK.
How the intervention might work
Screening uptake may be determined by client- or service-related
factors (Bonfill Cosp 2001; Jepson 2000). Studies that examined
the reasons for non-uptake of cancer screening in people with
SMI identified similar reasons for individuals with and without
mental illness (Martens 2009; Owen 2002; Werneke 2006). Rea-
sons for non-uptake included low income, increasing age, lack of
transport, embarrassment, lack of reminders and lack of familiar
care providers. Interventions found to increase screening uptake
in other populations may therefore also be effective in people with
SMI. However, one study (Dickerson 2003) found that people
with SMI were more likely to perceive barriers to receiving med-
ical care than those in a matched sample from the general pop-
ulation, so individualised consideration of perceived barriers or
more intensive counselling to address barriers may be necessary
in people with SMI. Qualitative research (Miller 2007) suggests
that poor communication between primary care and psychiatric
services may also contribute to reduced screening uptake, so in-
terventions that address this may also be important.
Why it is important to do this review
Cancer screeningmay be especially important for people with SMI
who may be at increased risk of some cancers and of worse cancer
outcome (Howard 2010). However, there is a reduced uptake of
screening in this population (Howard 2010). Systematic reviews
(Bonfill Cosp 2001; Jepson 2000) have demonstrated the effec-
tiveness of a range of interventions to increase cancer screening
uptake. However, there are likely to be both client-related and
service-related barriers to uptake of screening which are specific
to people with SMI. This review is needed to determine whether
interventions tailored to the needs of people with SMI are effective
in increasing their uptake of cancer screening.
O B J E C T I V E S
To determine the effectiveness of interventions targeted at adults
with severe mental illness (SMI) (i.e. schizophrenia or other re-
lated psychotic disorders and bipolar disorder), or their carers or
health professionals, and aimed at increasing the uptake of cancer
screening tests for which the adults with SMI are eligible.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
All relevant randomised controlled trials (RCTs). If trials were de-
scribed as ’double blind’ but implied randomisation, we planned to
include such trials in a sensitivity analysis (see Sensitivity analysis).
If their inclusion did not result in a substantive difference, they
would have remained in the analyses. If their inclusion did result
in statistically significant differences, we would not have added the
data from these lower quality studies to the results of the better
trials, but would have presented such data within a subcategory.
Quasi-randomised studies, such as those allocating by alternate
days of the week, were not eligible for inclusion.
Types of participants
Male and female participants (aged 18 years and over) with SMI
(i.e. schizophrenia or other related psychotic disorders and bipo-
lar disorder), however diagnosed, being treated in any setting and
who were eligible for any cancer screening programme (e.g. for
cervical, breast, prostate, colorectal cancer) as defined by the entry
criteria for that programme. Those people due, overdue, return-
ing for a repeat test or returning for follow-up subsequent to an
abnormal test were eligible for inclusion. We planned to include
trials where participants had only the designation of having SMI,
but not include those trials where bipolar was the sole diagnosis.
We would have included study participants with substance abuse
disorders co-morbidwith SMI. Since people with non-severemen-
tal illness (e.g. anxiety disorder, depression) may be more likely
to attend screening, possibly due to increased contact with health
care (Carney 2006), we planned to include studies with popula-
tions involving people with non-severe mental disorders only if
at least 80% of participants had SMI, or if data limited to those
with SMI were available. Trials of study participants with SMI and
concomitant physical illness were also eligible for inclusion.
Types of interventions
1. Intervention target
Studies of interventions targeted at adults with SMI, or their car-
ers or health professionals or both, and aimed at increasing the
uptake of cancer screening tests for which the adults with SMI
were eligible. Interventions targeted at health professionals specif-
ically had to relate to increasing uptake of screening in people with
SMI, as interventions aimed at health professionals to increase
overall screening uptake are the subject of other Cochrane reviews
(Freemantle 1997; Gordon 1998; Gorman 1998; Hulscher 2006;
Ivers 2012; OBrien 2001; Romero 2004).We intended to exclude
studies with interventions aimed at populations, such as mass me-
dia campaigns, as these have been covered by another Cochrane
review (Grilli 2000) and the studies are unlikely to be targeted at
those with SMI.
2. Cancer screening tests
Cancer screening tests may be universal (aimed at the entire
population), selective (aimed at specific groups) or opportunistic
(screening is proposed during a normal consultation) and aimed
at detecting the presence or absence of cancer during the pre-
symptomatic phase or before clinical detection. Screening proce-
dures should involve a healthcare professional; examples include:
mammography, cervical ‘Papanicolaou’ smears, colorectal cancer
screening and prostatic cancer screening (prostate-specific antigen
(PSA) test, digital rectal examination). This is not an exhaustive
list. We excluded studies of self-examination procedures, such as
breast or testicular self-examination.
3. Intervention type
Any type of intervention was eligible for inclusion; for instance,
invitations, reminders, education, counselling, use of technology
such as mobile phones and email, interventions to improve access,
procedural changes to increase acceptability, incentives or removal
of financial barriers, office systems or audit. Interventions could
be specific to a particular cancer screening test or could include
invitations to other healthcare services.
We planned to exclude interventions focused on promoting ‘in-
formed uptake’ unless they included screening uptake as a sec-
ondary outcome. This is because it is recognised that the con-
cept of informed uptake is complex: screeningmay have associated
harms as well as benefits, non-uptake can also be informed; indi-
vidual choice should be respected (Jepson 2000) and provision of
risk information may sometimes lead to reduced uptake (Edwards
2006).
Studies that sought only to measure the psychological impact of
screening or intention to undertake screening unless screening up-
take was reported as a secondary outcome were not eligible for
inclusion. We also planned to exclude studies concerning compul-
sory screening (for example, in prisons or secure units) or hypo-
thetical decisions to participate in screening.
4. Control
No intervention or usual care as defined by the study authors. We
planned to record and assess details of the usual care for hetero-
geneity between studies.
Types of outcome measures
Primary outcomes
1. Uptake of screening
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1.1 Uptake of screening as recorded by health service records
(such as screening administration system, hospital or primary care
records)
1.2 Uptake of screening as collected via self-report (i.e. directly
reported by the participant in a telephone interview or question-
naire)
Secondary outcomes
1. Attitudes to screening as measured by the study authors
1.1 Satisfaction with screening
1.2 Decisional conflict
1.3 Clinically significant change in anxiety
1.4 Any change in anxiety
1.5 Clinically significant change in emotional wellbeing
1.6 Any change in emotional wellbeing
2. Knowledge of screening as measured by the study authors
2.1 Any change in knowledge of eligibility for tests
2.2 Any change in knowledge of cancer risk
2.3 Any change in accurate cancer risk perception
3. Reported intention to attend screening (i.e. directly
reported by the participant in a telephone interview or
questionnaire)
4. Booking of appointments as recorded in health service
records
5. Economic outcomes
5.1 Direct costs of the intervention
5.2 Indirect costs
6. Intervention acceptability
6.1Number of participants leaving the trial early - total proportion
leaving the study early
6.2 Number of participants who left the study early due to adverse
events during the trial - proportion leaving the study early due to
adverse events
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
OnJuly 4, 2016, the information specialist searched the the register
using the following search strategy:
*Cancer* in Health Care Condition Field of STUDY
In such study-based register, searching the major concept retrieves
all the relevant keywords and studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE,MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group’s
Module). There is no language, date, document type, or publica-
tion status limitations for inclusion of records into the register.
For previous searches, please see Appendix 1.
Searching other resources
1. Reference searching
We planned to search the bibliographies of all retrieved articles
for additional references. We would have recorded the number of
cited trials not detected by the electronic search as a measure of
the sensitivity of the electronic search.
2. Personal communication
We planned to contact the authors of all the included studies and
authors with at least two publications amongst those studies that
we excluded, but which appeared related to the review, to ask if
they knew of any study which met the inclusion criteria of this
review.Thiswould have helped to identify unpublished or ongoing
studies.
Data collection and analysis
Selection of studies
Two review authors (EB and RB) independently examined the ti-
tles and abstracts of studies identified by the above searches for
relevance. The full text of studies deemed potentially relevant by
either author would have been obtained if we had identified suit-
able studies. The same two review authors would have then in-
dependently assessed each text for eligibility based on the above
inclusion criteria. We planned to calculate inter-rater agreement
using Cohen’s Kappa and report results. Disagreements would
have been resolved by discussion until consensus was reached. We
would have recorded any excluded and included studies. If it was
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not possible to obtain sufficient information to judge whether a
study was eligible for inclusion, we would have recorded the study
as ‘awaiting assessment’.
Data extraction and management
Two review authors (EB and RB) would have independently ex-
tracted data using data extraction forms. We would have piloted
the data extraction forms and extracted the following data from
each trial: number of participants in each condition; age and gen-
der of participants; type of mental disorder; study location and set-
ting; type of cancer screening test; testing stage (i.e. due, overdue,
returning for a repeat test or returning for follow-up subsequent
to an abnormal test); type of control condition; length of follow-
up; type, duration, intensity and theoretical basis (if applicable) of
intervention undertaken; data for assessment of risk of bias; pri-
mary and secondary outcome measures. We would have published
these data in an appendix. In the case of missing data, we would
have made up to two attempts to contact the trial authors. We
would have resolved disagreements by discussion between authors
(EB and RB) and by referral to a third author (PW).
Assessment of risk of bias in included studies
Again, EB and RB working independently, would have assessed
risk of bias by using criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) to assess trial
quality. This set of criteria is based on evidence of associations
between overestimate of effect and high risk of bias of the article
such as sequence generation, allocation concealment, blinding,
incomplete outcome data and selective reporting.
If the raters disagreed, we would have made the final rating by
consensus, with the involvement of another member of the re-
view group. Where inadequate details of randomisation and other
characteristics of trials were provided, we would have contacted
authors of the studies in order to obtain further information. We
would have reported non-concurrence in quality assessment, but
if disputes arose as to which category a trial was to be allocated,
again, we would have achieved resolution by discussion.
We planned to note the level of risk of bias in both the text of the
review and in the ’Summary of findings’ table.
Measures of treatment effect
1. Dichotomous data
For each study described as ‘randomised’, we would have calcu-
lated risk ratio (RR) with 95% confidence intervals (CI). Within
a meta-analysis (see below), we would have combined compara-
ble dichotomous measures by calculating an overall RR and 95%
CI. We chose RR over the odds ratio because the latter tends to
overstate effect size when event rates are high (Higgins 2011).
2. Continuous data
2.1 For each study, we planned to calculatemean differences (MD)
with 95% CIs for comparisons of continuous outcome measures.
Within a meta-analysis (see below), we planned to calculate MD
scores and 95% CIs for comparisons of continuous data from the
same or similar scales, and standardised mean differences (SMD)
where an outcome has been measured differently across studies.
If we had calculated SMD, we would have transformed the effect
back to the units of one or more of the specific instruments. This
would have aided the interpretation of the clinical relevance and
impact of the intervention effect.
2.2 Data synthesis: if standard errors (SEs) instead of standard
deviations (SDs) were presented, we planned to convert the former
to SDs. If SDs were not reported and we could calculate them
from available data, we planned to ask study authors to supply the
data. In the absence of data from authors, we would have used the
mean SD from other studies (Furukawa 2006).
2.3 Skewed data:continuous data on clinical and social outcomes
are often not normally distributed. To avoid the pitfall of applying
parametric tests to non-parametric data, we aimed to apply the
following standards to all data before inclusion: a) SDs and means
are reported in the paper or obtainable from the authors; b) when
a scale starts from the finite number zero, the SD, whenmultiplied
by two, is less than the mean (as otherwise the mean is unlikely to
be an appropriatemeasure of the centre of the distribution (Altman
1996); c) if a scale started from a positive value the calculation
described abovewould have beenmodified to take the scale starting
point into account. In these cases skew is present if 2 SD > (S-
S min), where S is the mean score and S min is the minimum
score. Endpoint scores on scales often have a finite start and end
point and these rules can be applied. When continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether data are skewed
or not. We would have entered skewed data from studies of fewer
than 200 participants as other data within the data and analyses
section rather than into a statistical analysis. Skewed data pose less
of a problem when looking at means if the sample size is large and
would have been entered into syntheses.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by ward or GP surgery), but analysis and pooling of
clustered data poses problems. Authors often fail to account for
intra-class correlation in clustered studies, leading to a ’unit of
analysis’ error (Divine 1992), whereby P values are spuriously low,
CIs unduly narrow and statistical significance overestimated. This
causes Type I errors (Bland 1997; Gulliford 1999).
If clustering had not been accounted for in primary studies, we
planned to present data in a table, with a (*) symbol to indicate
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the presence of a probable unit of analysis error. In subsequent
versions of this review, if we find such cluster studies, we will
seek to contact first authors of these studies to obtain intra-class
correlation coefficients (ICCs) for their clustered data and to adjust
for this by using accepted methods (Gulliford 1999).
If clustering had been incorporated into the analysis of primary
studies, we planned to present these data as if from a non-cluster
randomised study, but adjust for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’de-
sign effect’. This is calculated using the mean number of partici-
pants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC]
(Donner 2002). If the ICC was not reported, we would assume
it to be 0.1 (Ukoumunne 1999). If cluster studies have been ap-
propriately analysed taking into account ICCs and relevant data
documented in the report, synthesis with other studies may be
possible using the generic inverse variance technique.
2. Cross-over trials
Cross-over trials for these types of intervention are unlikely, but
we would have considered them as follows. A major concern of
cross-over trials is the carry-over effect. It occurs if an effect (e.g.
pharmacological, physiological or psychological) of the treatment
in the first phase is carried over to the second phase. As a conse-
quence, on entry to the second phase the participants can differ
systematically from their initial state despite a wash-out phase. For
the same reason, cross-over trials are not appropriate if the con-
dition of interest is unstable (Elbourne 2002). As both effects are
very likely in severe mental illness, we would only have used data
of the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved two or more intervention groups com-
pared against a control, if relevant, we planned to present the addi-
tional intervention groups in additional comparisons. If data were
continuous, we would have combined data following the formula
in section 7.7.3.8 (Combining groups) of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). If the addi-
tional treatment arms were not relevant, we would not have repro-
duced these data. For dichotomous data, we planned to collapse
active treatment groups into a single arm for comparison against
the control group, or split the control group equally into two.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them within analyses, except for the outcome of
leaving the study early. If, however, more than 50% of those in
one arm of a study were lost, but the total loss was less than 50%,
we would mark such data with (*) to indicate that such a result
may well be prone to bias.
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we
planned to present data on a ’once-randomised-always-analyse’ ba-
sis (an intention-to-treat analysis). We would have assumed those
leaving the study early to have the same rates of negative outcome
as those who completed. We planned to undertake a sensitivity
analysis to test how prone the primary outcomes were to change
when ’completer’ data only were compared to the intention-to-
treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50% and completer-only data were reported, we would
have reproduced these.
3.2 Standard deviations (SDs)
If SDs were not reported, we planned first try to obtain themissing
values from the authors. If not available, where there were missing
measures of variance for continuous data, but an exact SE and CIs
available for group means, and either P value or T value available
for differences in mean, we could have calculated them accord-
ing to the rules described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). When only the SE are
reported, SDs are calculated by the formula SD = SEx
√
n. Chap-
ters 7.7.3 and 16.1.3 of the Cochrane Handbook (Higgins 2011)
present detailed formulae for estimating SDs from P values, T or
F values, CIs, ranges or other statistics. If these formulae did not
apply, we would have calculated the SDs according to a validated
imputation method which is based on the SDs of the other in-
cluded studies (Furukawa 2006). Although some of these impu-
tation strategies can introduce error, the alternative would be to
exclude a given study’s outcome and thus to lose information. We
nevertheless planned to examine the validity of the imputations
in a sensitivity analysis excluding imputed values.
3.3 Last observation carried forward
We anticipate that in some studies the method of last observation
carried forward (LOCF) will be employed within the study report.
As with all methods of imputation to deal with missing data,
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LOCF introduces uncertainty about the reliability of the results
(Leucht 2007). Therefore, where LOCF data have been used in
the trial, if less than 50% of the data have been assumed, we would
reproduce these data and indicate that they are the product of
LOCF assumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
We planned to consider all included studies initially, without see-
ing comparison data, to judge clinical heterogeneity. We would
simply have inspected all studies for clearly outlying people or sit-
uations which we had not predicted would arise. If such situations
or participant groups arose, we would have discussed these fully.
2. Methodological heterogeneity
We planned to consider all included studies initially, without see-
ing comparison data, to judge methodological heterogeneity. We
would simply have inspected all studies for clearly outlying meth-
ods which we had not predicted would arise. If such methodolog-
ical outliers arose, we would have discussed these fully.
3. Statistical heterogeneity
3.1 Visual inspection
We planned to visually inspect graphs to investigate the possibility
of statistical heterogeneity.
3.2 Employing the I2 statistic
We planned to investigate heterogeneity between studies by con-
sidering the I2 method alongside theChi2 P value. The I2 provides
an estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I
2 depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi2 test, or a
confidence interval for I2). We would have interpreted an 12 esti-
mate greater than or equal to around 50% accompanied by a sta-
tistically significant Chi2 statistic as evidence of substantial levels
of heterogeneity (Section 9.5.2 - Higgins 2011). If we had found
substantial levels of heterogeneity in the primary outcome, we
would have explored reasons for heterogeneity (Subgroup analysis
and investigation of heterogeneity).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We are aware
that funnel plots may be useful in investigating reporting biases,
but are of limited power to detect small-study effects. In future
updates of this review, we will not use funnel plots for outcomes
where there are 10 or fewer studies, or where all studies are of
similar sizes. In other cases, where funnel plots are possible, we
will seek statistical advice in their interpretation.
Data synthesis
Where there were sufficient data, we planned to perform meta-
analyses. The random-effects method incorporates an assumption
that the different studies are estimating different, yet related, inter-
vention effects and takes into account differences between studies
even if there is no statistically significant heterogeneity. A disad-
vantage of the random-effects model is that it puts added weight
onto small studies, which often are themost biased ones. Depend-
ing on the direction of effect, these studies can either inflate or
deflate the effect size.We planned to use the random-effects model
for all analyses, but would have tested in a sensitivity analysis of
the primary outcome what happens if we hadv used a fixed-effect
model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses - only primary outcomes
1.1 Intervention target
We proposed to undertake this review and provide an overview
of the effects of any intervention to increase cancer screening up-
take in people with severe mental illness. In addition, however,
we planned to examine the effects of differential targeting of the
interventions to people with SMI, carers, health professionals or
a combination of the above.
1.2 Intervention
If there were sufficient data, we planned also investigate the effects
of: type of cancer screening test - for example breast, cervical,
prostate, bowel; intervention type; setting - for example primary
care, care home, hospital.
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2. Investigation of heterogeneity
First, we planned to investigate whether data had been entered
correctly. Second, if data were correct, we would have visually in-
spected the graph and successively removed outlying studies to see
if homogeneity was restored.Wewould have reported this. For this
review, we decided that should this occur with data contributing
to the summary finding of no more than around 10% of the total
weighting, we would present data. If not, we would not pool data
and would discuss issues. We know of no supporting research for
this 10% cut off but are investigating use of prediction intervals
as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity was
obvious, we would simply state hypotheses regarding these for
future reviews or versions of this review. We did not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way as to imply randomisation. For the primary
outcomes, we planned to include these studies and if there was no
substantive difference when the implied randomised studies were
added to those with better description of randomisation, then we
would have used all data from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data), we planned to compare
the findings of the primary outcomes when we used our assump-
tion compared with completer data only. If there was a substantial
difference, we would have reported results and discussed them but
continued to employ our assumption.
Where assumptions have to be made regarding missing SDs data
(see Dealing with missing data), we planned to compare the find-
ings on primary outcomes when we used our assumption com-
pared with complete data only. We planned to undertake a sen-
sitivity analysis to test how prone results were to change when
’completer’ data only were compared to the imputed data using
the above assumption. If there had been a substantial difference,
we would have reported results and discussed them but continued
to employ our assumption.
3. Risk of bias
We planned to analyse the effects of excluding trials judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available):
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias did not substantially alter the direction of effect or
the precision of the effect estimates, then we would have included
data from these trials in the analyses.
4. Imputed values
Weplanned also undertake a sensitivity analysis to assess the effects
of including data from trials where we used imputed values for
ICC in calculating the design effect in cluster randomised trials.
If we had noted substantial differences in the direction or precision
of effect estimates in any of the sensitivity analyses listed above,
we would not have pooled data from the excluded trials with the
other trials contributing to the outcome, but would have presented
them separately.
5. Fixed-effect and random-effects
Weplanned to synthesise data using a random-effects model; how-
ever, wewould also have synthesised data for the primary outcomes
using a fixed-effect model. This would have determined whether
the greater weights assigned to larger trials with greater event rates
altered the significance of the results compared to the more evenly
distributed weights in the random-effects model.
R E S U L T S
Description of studies
Results of the search
We identified 158 citations. Itwas clear from the titles and abstracts
that none were relevant, therefore, we did not obtain the full texts.
Included studies
No studies met the inclusion criteria for this review.
Excluded studies
It was clear from titles and abstracts that no identified study even
potentially met the eligibility criteria for this review.
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Studies awaiting assessment
No studies are currently awaiting assessment.
Ongoing
We are not aware of any relevant ongoing studies.
Risk of bias in included studies
No studies met the inclusion criteria for this review.
Allocation
No studies met the inclusion criteria for this review.
Blinding
No studies met the inclusion criteria for this review.
Incomplete outcome data
No studies met the inclusion criteria for this review.
Selective reporting
No studies met the inclusion criteria for this review.
Other potential sources of bias
No studies met the inclusion criteria for this review.
Effects of interventions
No studies met the inclusion criteria for this review.
D I S C U S S I O N
Summary of main results
We did not find any randomised controlled trials (RCTs) of any
intervention to encourage uptake of any form of cancer screening
compared with no intervention or usual care in adults with severe
mental illness (SMI).There is currently no adequate evidence base
to support any intervention to encourage cancer screening uptake
for people with SMI.
Overall completeness and applicability of
evidence
The Cochrane Schizophrenia Group’s register is the most compre-
hensive trials register of its kind, a detailed search was devised yet
none of the identified trials even potentially met the inclusion cri-
teria. The reason for the identification of the 158 citations tended
to be that they referred to cancer either as a possible side-effect
of a treatment being tested in people with SMI or as an exclusion
criterion for participation in the reported trial. One of the review
authors (EB) has contributed previously to a detailed review of
the literature concerning cancer in people with SMI published in
Lancet Oncology (Howard 2010); no trials of interventions to in-
crease cancer screening uptake in people with SMI were identified
through that work either.
Quality of the evidence
Despite lack of uptake of cancer screening by people with SMI
comparedwith others, there is no evidence to support how this dis-
parity can be reduced. Interventions to encourage cancer screen-
ing uptake in people with SMI are needed and should be tested in
large, multi-centre RCTs.
Potential biases in the review process
No potential biases could be determined apart from the fact that
our search was mainly based on the register of the Cochrane
Schizophrenia Group. While extensive methodological searches
are continuously run for this register, it is still largely based on
published trials, but there maybe unpublished studies that we are
not aware of.
Agreements and disagreements with other
studies or reviews
To our knowledge, no similar review has been conducted.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with severe mental illness
There is currently no high quality research evidence to suggest that
any particular intervention would encourage a person with severe
mental illness to take up cancer screening.
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2. For clinicians
Early detection of cancer through screening is effective in improv-
ing patient outcomes including death.Given that people with SMI
are at greater risk of cancer but less likely than others to take up
available screening, implementation of appropriate and effective
interventions to encourage cancer screening uptake is needed ur-
gently. Potentially, this could be addressed by a range of profes-
sionals in a variety of healthcare settings including mental health,
primary and social care. Since there is currently no evidence avail-
able from randomised controlled trials to allow assessment of the
efficacy of any specific intervention to encourage uptake of cancer
screening for people with severe mental illness, clinicians will have
to rely on their personal experience and clinical judgement when
discussing with individuals the importance of taking up cancer
screening opportunities.
3. For policy and decision makers
Currently, policy makers have no trial-based evidence upon which
to base guidelines for promoting cancer screening uptake in people
with severe mental illness. Funding bodies may wish to make this
a priority for future research in order to reduce the health disparity
between people with and without severe mental illness which will
result from lower uptake by the former of cancer screening.
Implications for research
1. General
This review has highlighted the absence of RCTs investigating the
efficacy of interventions to encourage cancer screening uptake by
people with SMI. Given the increased morbidity and mortality
of people with SMI, for instance, the Schizophrenia Commis-
sion (Schizophrenia Commission 2012) reports that people with
schizophrenia who develop cancer are three times more likely to
die than those in the general population with cancer, it is surpris-
ing that there has been so little research in this area. The reasons
for this are unclear. In order to develop effective, evidence-based
interventions, there is an urgent need for high-quality RCTs.
2. Specific
Future interventions should address known barriers to screen-
ing uptake, including low income, increasing age, lack of trans-
port, embarrassment, lack of reminders, and lack of familiar care
providers (Howard 2010). Research is also needed to identify
whether there are barriers specific to people with SMI which may
inhibit cancer screening uptake and which could be addressed in
a future intervention (Howard 2010). In order to facilitate future
meta-analyses, reports of trials of interventions to encourage can-
cer screening uptake in people with SMI should comply fully with
the latest CONSORT guidance (Moher 2010).
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The Cochrane Schizophrenia Group Editorial Base in Notting-
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section of their reviews. We have used this text as the basis of what
appears here and adapted it as required.
TheCSG register searchwas conducted by the Trial SearchCo-Or-
dinator of the Cochrane Schizophrenia group, Samantha Roberts.
We would like to thank Chris Jones for peer reviewing this review,
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Previous searches
Search in 2012, 2014, and 2015
Electronic searches
Cochrane Schizophrenia Group’s Trials Register
The Trials Search Coordinator (TSC) searched the Cochrane Schizophrenia Group’s Registry of Trials (October 25, 2012; December
19, 2014; April 07, 2015) using the following search strategy:
(*cancer* OR *neoplasms* OR *mass screening* OR *maligna* OR *tumour*) in Title, Abstract and Index Terms Fields of REFER-
ENCE
The Cochrane Schizophrenia Group’s Registry of Trials is compiled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group’s Module). There is no language, date, document type, or publication
status limitations for inclusion of records into the register.
Searching other resources
1. Reference searching
We planned to search the bibliographies of all retrieved articles for additional references. We would have recorded the number of cited
trials not detected by the electronic search as a measure of the sensitivity of the electronic search.
2. Personal communication
We planned to contact the authors of all the included studies and authors with at least two publications amongst those studies that we
excluded, but which appeared related to the review, to ask if they knew of any study which met the inclusion criteria of this review.
This would have helped to identify unpublished or ongoing studies.
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WH A T ’ S N E W
Last assessed as up-to-date: 4 July 2016.
Date Event Description
7 September 2016 New citation required but conclusions have not
changed
Update search completed. Conclusions unchanged.
4 July 2016 New search has been performed Update search conducted. No new studies found.
7 April 2015 Amended Update search conducted. No new studies found.
H I S T O R Y
Protocol first published: Issue 2, 2012
Review first published: Issue 7, 2013
Date Event Description
19 December 2014 Amended Update search conducted. No new studies found. Assessed as Up-to-date amended
C O N T R I B U T I O N S O F A U T H O R S
Elizabeth Barley - proposed the review, helped write the protocol, contributed to formulating searches, screened studies and wrote the
review.
Rohan Borschmann - helped write the protocol, screened studies and contributed to writing the review.
Paul Walters - commented on drafts of the protocol, helped arbitrate disagreements and commented on drafts of the review.
Andree Tylee - commented on drafts of the protocol and of the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• King’s College London, UK.
EB, RB and AT are employed by King’s College London
• Dorset Healthcare University Foundation Trust, UK.
PW is employed by Dorset Healthcare University Foundation Trust
External sources
• None provided, Other.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Bipolar Disorder; ∗Early Diagnosis; ∗Psychotic Disorders; ∗Schizophrenia; Early Detection of Cancer [∗utilization]; Risk
MeSH check words
Adult; Humans
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